Nuscale Power earnings missed by $0.02, revenue fell short of estimates
Insmed (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $19.55 billion, saw its Chief Legal Officer Michael Alexander Smith sell a total of 1,681 shares of common stock in two separate transactions. The stock has shown remarkable strength, gaining over 46% in the past six months according to InvestingPro data.
On July 11, 2025, Smith sold 748 shares at a price of $96.41, totaling $72,114. These shares were sold to cover tax obligations related to the vesting of Restricted Stock Units and broker fees.
On July 15, 2025, Smith sold 933 shares at a weighted average price of $102.51, for a total of $95,641. The prices for these shares ranged from $102.37 to $102.70. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on February 27, 2025.
Following these transactions, Smith directly owns 66,394 shares of Insmed. This includes 357 shares acquired through the company’s 2018 Employee Stock Purchase Plan.
In other recent news, Insmed Incorporated has announced a public offering of common stock priced at $96.00 per share, expected to generate approximately $750 million in gross proceeds. The company plans to use the funds for research and development, including the commercialization of ARIKAYCE and further development of treprostinil palmitil inhalation powder (TPIP). Additionally, Insmed has announced another public offering aiming to raise $650 million, with Goldman Sachs & Co. LLC and Leerink Partners as joint book-running managers.
Analyst firms have reacted positively to Insmed’s recent developments, with Mizuho (NYSE:MFG) reiterating its Outperform rating and RBC Capital raising its price target to $106, citing strong data for TPIP in pulmonary arterial hypertension (PAH) treatment. RBC described the PAH data as exceeding expectations and projected TPIP revenue of $2.2 billion by 2034. H.C. Wainwright also increased its price target to $120, maintaining a Buy rating following positive Phase 2A and Phase 2B study results for TPIP. These developments suggest a positive outlook for Insmed’s TPIP program and its potential impact on the company’s future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.